What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?
What benefit can be derived from treating normocholesterolemic patients with coronary artery disease?
复制标题
治疗患有冠状动脉疾病的胆固醇正常的患者可以获得什么益处？
DOI：
10.1016/s0002-9149(99)80477-9
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Albers,JJ
中科院分区：
文献类型：
--
作者：
Brown,G;Stewart,BF;Zhao,XQ;Hillger,LA;Poulin,D;Albers,JJ
对于冠状动脉疾病且血脂水平明显正常的患者，强化调脂治疗可能带来的临床或动脉造影益处仍存在争议。这一争议的解决似乎取决于对总或低密度脂蛋白胆固醇水平以外的变量作用的更好理解。对家族性动脉粥样硬化治疗研究患者和哈佛动脉粥样硬化可逆性项目患者中的“降血脂”亚组进行的比较表明，低水平的高密度脂蛋白胆固醇和高水平的载脂蛋白B似乎大大增加了从强化调脂治疗中获益的可能性。其他与风险相关的变量，如收缩压和脂蛋白(A)，进一步有助于风险的预测，并可能有助于治疗受益的可能性。
Controversy still remains regarding the possible clinical or arteriographic benefit of intensive lipid-altering therapy in patients who have coronary artery disease and apparently normal lipid levels. Resolution of this controversy appears to depend on an improved understanding of the role of variables other than total or low density lipoprotein cholesterol levels. A comparison of the “normolipidemic” subgroup of The Familial Atherosclerosis Treatment Study patients and The Harvard Atherosclerosis Reversibility Project patients indicates that low levels of high density lipoprotein cholesterol and elevated levels of apolipoprotein B appear to increase considerably the likelihood of benefit from intensive lipid-altering therapy. Other risk-related variables such as systolic blood pressure and lipoprotein(a) further contribute to the prediction of risk and possibly to the potential for treatment benefit.